

Pharmacy Oncology Symposium September 19th, 2026

Agenda

7:30am – 7:55 am Registration and breakfast

8:00 am – 8:05 am Welcome/Greeting
Jordan Scott, PharmD

8:00 – 9:00 am **NYS Pharmacy Law 2026 & Medical Aid in Dying (60 min)**
Dr. Christopher Jadoch, PharmD, JD (email: christopher.jadoch@roswellpark.org)

1. Objective #1 Describe the role of pharmacy in NYS Medical Aid in Dying (MAiD) law
2. Objective #2 Outline the MAiD procedure in NYS
3. Objective #3 Identify Updates in NYS Laws Affecting the Practice of Pharmacy

9:00 – 10:00 am **"Here Come the Men-in-Black" the Newest Agents in the War Against AML (60min)**
Dr. Jeffrey Baron, PharmD, BCOP (email: Jeffrey.Baron@roswellpark.org)

- Objective #1 Describe the prognostic significant & treatment implications of KMT2Ar & NPM1m in AML
- Objective #2 Discuss key clinical pearls to develop monitoring plans to optimize menin inhibitor therapy
- Objective #3 Summarize the clinical literature of menin inhibitors both for FDA approved agents & agents in pipeline

10:00 am – 10:20am Break

10:20 – 11:20 am **Keynote: Human-Centered Leadership in the Age of AI and Healthcare Burnout (60 min)**
Dr. Alex Varkey, PharmD, MS, FAPhA (email: avarkey@visante.com)

- Objective #1 Explain how human-centered leadership influences engagement and organizational culture
- Objective #2 Describe the impact of artificial intelligence (AI) and rapid change on trust, resilience, and professional fulfillment
- Objective #3 Identify leadership strategies that support innovation while preserving human connection

11:20 am- 12:05 pm Lunch Break

12:05 am – 1:05 pm **Give Me a BRCA: Navigating the Treatment of HRRm Metastatic Prostate Cancer (60min)**

Dr. Bryan Fitzgerald, PharmD, BCOP(email: bryan.fitzgerald@roswellpark.org)

- Objective #1 Review the pathophysiology behind homologous recombination repair-mutated (HRRm) metastatic prostate cancer and the role of poly (ADP-ribose) polymerase (PARP) inhibitors
- Objective #2 Describe the results of key clinical trials to support the use of PARP inhibitors to treat HRRm metastatic prostate cancer
- Objective #3 Summarize the indications and roles in therapy of available PARP inhibitors for treating HRRm metastatic prostate cancer
- Objective #4 Define key counseling points, monitoring parameters, and clinical considerations for PARP inhibitors

1:05pm - 2:05 pm **Know Your ABCs: Prevention and Management of Viral Hepatitis**

Dr. Joseph Elijah, PharmD, MBA, BCOP, BPS (email:j.elijah@northeastern.edu)

1. Objective #1 Describe the risk factors, modes of transmission, and infection cycles associated with the different hepatitis virus
2. Objective #2 Explain the interpretation of hepatitis B serologic panels and their role in determining infection status and informing prevention and treatment strategies
3. Objective #3 Discuss the therapeutic goals of hepatitis B treatment and the drug- and patient-specific factors that influence therapy selection and monitoring.

2:05-2:15 pm Closing Remarks
Jordan Scott, PharmD